HLI98, a novel small molecule targeting the ubiquitin ligase MDM2, specifically inhibits MDM2 to activate the p53 signaling pathway to inhibit cancer occurrence and development in CRC (Vassilev 2007). The gene discussed is TP53; the disease is cancer.